sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1α signaling pathways

Boh Ram Kim, Seung Hee Seo, Mi Sun Park, Seung Hoon Lee, Youngjoo Kwon, Seung Bae Rho

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


The suppressor of MEK null (sMEK1) protein possesses pro-apoptotic activities. In the current study, we reveal that sMEK1 functions as a novel anti-angiogenic factor by suppressing vascular endothelial growth factor (VEGF)-induced cell proliferation, migration, and capillary-like tubular structure in vitro. In addition, sMEK1 inhibited the phosphorylation of the signaling components up- and downstream of Akt, including phospholipase Cγ1 (PLC-γ1), 3-phosphoinositide-dependent protein kinase 1 (PDK1), endothelial nitric oxide synthetase (eNOS), and hypoxia-inducible factor 1 (HIF-1α) during ovarian tumor progression via binding with vascular endothelial growth factor receptor 2 (VEGFR-2). Furthermore, sMEK1 decreased tumor vascularity and inhibited tumor growth in a xenograft human ovarian tumor model. These results supply convincing evidence that sMEK1 controls endothelial cell function and subsequent angiogenesis by suppressing VEGFR-2-mediated PI3K/Akt/eNOS signaling pathway. Taken together, our results clearly suggest that sMEK1 might be a novel antiangiogenic and anti-tumor agent for use in ovarian tumor.

Original languageEnglish
Pages (from-to)31830-31843
Number of pages14
Issue number31
StatePublished - 2015


  • Anti-angiogenic activity
  • Hypoxic condition
  • Ovarian tumor
  • Xenograft model
  • sMEK1 tumor suppressor


Dive into the research topics of 'sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1α signaling pathways'. Together they form a unique fingerprint.

Cite this